ESP 24232

Drug Profile

ESP 24232

Latest Information Update: 29 Apr 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Esperion Therapeutics
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Diabetes mellitus; Low HDL cholesterol

Most Recent Events

  • 29 Apr 2002 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
  • 29 Apr 2002 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
  • 29 Apr 2002 Discontinued - Preclinical for Low HDL cholesterol in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top